Mannino Federica, Bitto Alessandra, Irrera Natasha
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Front Pharmacol. 2020 Nov 26;11:592169. doi: 10.3389/fphar.2020.592169. eCollection 2020.
The new coronavirus outbreak was first identified in Wuhan, China, in December 2019, and has turned out to be a global health emergency, affecting millions of people worldwide. Coronavirus disease 19 (COVID-19), caused by the SARS-CoV-2 virus, can manifest with flu-like symptoms and can be complicated by severe pneumonia with acute respiratory distress syndrome (ARDS); however a large percentage of infected individuals do not have symptoms but contribute to the spread of the disease. Severe acute respiratory syndrome coronavirus-2 infection has become a global public health emergency since no available treatment seems effective and it is hard to manage the several complications caused by an intense release of cytokines. This paper reviews the current options on drugs used to reduce the deadly effects of the cytokine storm.
新型冠状病毒疫情于2019年12月在中国武汉首次被发现,现已演变成一场全球卫生突发事件,影响着全球数百万人。由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒引起的冠状病毒病19(COVID-19)可表现出流感样症状,并可能并发伴有急性呼吸窘迫综合征(ARDS)的严重肺炎;然而,很大一部分感染者没有症状,但却会导致疾病传播。由于似乎没有有效的可用治疗方法,且难以控制细胞因子大量释放所引起的多种并发症,严重急性呼吸综合征冠状病毒2感染已成为全球公共卫生突发事件。本文综述了目前用于减轻细胞因子风暴致命影响的药物选择。